“Committed to Excellence in Life Sciences Executive Search”

Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership with The Chase Group, Inc.

Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in advancing the clinical pipeline at Aeglea as they work to unlock the potential of engineered human enzymes to develop treatment options for patients with rare genetic diseases. The Chase Group is proud to connect this patient focused company with high caliber talent and wish Aeglea the best of success.

Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership with The Chase Group, Inc.

The Chase Group Successfully Completes Search for Vice President, Research & Development at Alexza Pharmaceuticals

The Chase Group Successfully Places David Geller, MD as Head of Pulmonary & Rare Disease Clinical Development for Arcturus Therapeutics

Drug Safety Leadership Team Grows at Ionis Pharmaceuticals Through Continued Partnership with The Chase Group

The Chase Group Continues Successful Collaboration with Genmab Through Placement of Vice President, CDTL

The Chase Group Successfully Secures Vice President, Head of Medical Development for Checkmate Pharmaceuticals

Search Executed by The Chase Group, Inc. Results in Successful Appointment of Dr. Christophe Hotermans as SVP, Global Medical Affairs for Akcea Therapeutics